ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P ASX 200
7,997.10
0.00%
S&P ASX All Technology
3,441.80
0.00%
Brent Oil
64.665
-2.06%
US Dollar vs AUD
1.5547
-0.80%
Bitcoin
94,625.39
0.94%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSXV

  6. Navion Capital II Inc (NVN.P) Share Price

Navion Capital II Inc

Navion Capital II Inc (NVN.P)

TSXV
0.055
0.00
(0.00%)
Closed 29 April 6:00AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.055
Bid
0.10
Offer
0.18
Volume
-
0.00 Day's Range 0.00
0.05 52 Week Range 0.115
Market Cap
253k
Previous Close
0.055
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
776
Shares Outstanding
4,600,000
Dividend Yield
-
PE Ratio
-2.25
Earnings Per Share (EPS)
-0.02
Revenue
-
Net Profit
-102k

About Navion Capital II Inc

Sector
Unit Inv Tr, Closed-end Mgmt
Industry
Unit Inv Tr, Closed-end Mgmt
Headquarters
Calgary, Alberta, Can
Founded
-
Navion Capital II Inc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the TSX Venture Exchange with ticker NVN.P. The last closing price for Navion Capital II was $0.06. Over the last year, Navion Capital II shares have traded in a share price range of $ 0.05 to $ 0.115.

Navion Capital II currently has 4,600,000 shares in issue. The market capitalisation of Navion Capital II is $253,000 . Navion Capital II has a price to earnings ratio (PE ratio) of -2.25.

Ask ADVFN Intelligence (AI)

NVN.P Latest News

More News
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.0550.0550.05500CS
40.005100.050.0550.052630.055CS
12-0.05-47.6190476190.1050.1050.057760.07277778CS
26-0.055-500.110.110.056870.08915052CS
52-0.055-500.110.1150.056510.09985225CS
156-0.045-450.10.1150.055950.10044871CS
260-0.045-450.10.1150.055950.10044871CS

NVN.P - Frequently Asked Questions (FAQ)

What is the current Navion Capital II share price?
The current share price of Navion Capital II is $ 0.055
How many Navion Capital II shares are in issue?
Navion Capital II has 4,600,000 shares in issue
What is the market cap of Navion Capital II?
The market capitalisation of Navion Capital II is CAD 253k
What is the 1 year trading range for Navion Capital II share price?
Navion Capital II has traded in the range of $ 0.05 to $ 0.115 during the past year
What is the PE ratio of Navion Capital II?
The price to earnings ratio of Navion Capital II is -2.25
What is the reporting currency for Navion Capital II?
Navion Capital II reports financial results in CAD
What is the latest annual profit for Navion Capital II?
The latest annual profit of Navion Capital II is CAD -102k
What is the registered address of Navion Capital II?
The registered address for Navion Capital II is #1250, 639 – 5TH AVENUE SW, CALGARY, ALBERTA, T2P 0M9
Which industry sector does Navion Capital II operate in?
Navion Capital II operates in the UNIT INV TR, CLOSED-END MGMT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VKG.HNorse Gold Corp
$ 0.03
(500.00%)
8k
EVMTEvome Medical Technologies Inc
$ 0.01
(100.00%)
54.81k
ZBNIZeb Nickel Corp
$ 0.07
(75.00%)
8k
CBLUClear Blue Technologies International Inc
$ 0.14
(64.71%)
67.5k
FHRFiddlehead Resources Corp
$ 0.18
(50.00%)
115k
NAVNAVCO Pharmaceuticals Inc
$ 0.005
(-50.00%)
30k
ALBT.PAlbatros Acquisition Corporation Inc
$ 0.005
(-50.00%)
2k
CRDCopper Road Resources Inc
$ 0.01
(-50.00%)
1,000
SSESilver Spruce Resources Inc
$ 0.005
(-50.00%)
1.5k
SOP.HSoperior Fertilizer Corp
$ 0.005
(-50.00%)
430.74k
FPCFalco Resources Ltd
$ 0.18
(0.00%)
9.62M
AFMAlphamin Resources Corp
$ 0.98
(11.36%)
2.4M
ADDArctic Star Exploration Corp
$ 0.015
(-25.00%)
2.33M
TVITVI Pacific Inc
$ 0.015
(0.00%)
1.75M
SIESienna Resources Inc
$ 0.025
(0.00%)
1.55M

Discussion

View Full Feed
imafan imafan 2 minutes ago
Eeyore has spoken! AKA professed lying short. Real News: HUUUUGE ANNOUNCEMENTS of HUUUUGE ACCOMPLISHMENTS IMMINENT!!! WHALES LURKING!!!
HHSE
StockItOut StockItOut 3 minutes ago
Another SmartyPants/Quester lie, or you have a filing to support your assertion?
XERI
fuagf fuagf 3 minutes ago
LOL Figured that comment would grab you. 🙃 Qualification to mine would be, of course, unless they had firm numbers wrapped up with more security than Fort Knox. While fully appreciating the gravity you see in the situation, and though I've read little lately, still am guessing it's better t
glenn1919 glenn1919 3 minutes ago
CTMX..............................................a/h
CTMX
dia76ca dia76ca 4 minutes ago
"Blarcamesine and Anavex 3-71 are changing the paradigm for the treatment of neurodegenerative and neurodevelopmental diseases."
Nice summary georgejjl !
Paradigm shifts are very exciting but some folks see them before others!
The rest of this year will be pivotal.
2026 s
AVXL
Lykiri Lykiri 4 minutes ago
Actually, there’s a bit of confusion here. Under the old regulation, both positive and negative recommendations were referred to the CHM for review. However, the new regulation (effective after 3 April 2025) stipulates that only applications with serious concerns are now referred to the CHM. Therefo
NWBO
I-Glow I-Glow 5 minutes ago
And the Hindenburg report.- https://hindenburgresearch.com/mullen/.

Plus, TenKay was all over the preferred shares and the financials.

IG
MULN
boi568 boi568 5 minutes ago
Even if an ADL "odds ratio" claim could normally be considered disqualifying in lieu of a comparison of the means, it just seems to me irrelevant to the EMA here, since ADL itself is a not ready for prime time EMA endpoint in an early AD trial.
AVXL
dennisdave dennisdave 5 minutes ago
I agree with your points . However there were medicines last year which got approved by MHRA but NICE decided not to get them covered by NHS same day or so. Those companies would have been in discussions with NICE before MHRA approval . So not really sure it is absolutely comforting Ok interesting
NWBO
hedge_fun hedge_fun 6 minutes ago
That’s what I said, you’re smarter than……

the markets.

In your opinion of course!
TSLA
WarMachine WarMachine 6 minutes ago
I couldn't imagine making such a fool of myself every day on a public forum.
You don't need to imagine it. LOL
they are beyond clueless about what's really happening here
Explain, IN DETAIL, with PROOF to validate your claims, EXACTLY what is going on here. Or is it YOU who is
MONI
Uncle Monkey Uncle Monkey 7 minutes ago
wow! huge MAGA action today. FSR

hahaha
CBRF
Natural Trader Natural Trader 7 minutes ago
it does with high PT
exwannabe exwannabe 7 minutes ago
Impossible, they have to by law. They cant simply stop discussion because NWBO "might" get refusal.
I do not claim to know how the MHRA-NICE communications work.

But I do think I understand the NICE process well enough. They are at hold waiting for the evidence submission. Ever
NWBO
Truenorth2016 Truenorth2016 8 minutes ago
Any Dip Before News IMO is a Golden Opportunity Set-up!!!
CAVR
skitahoe skitahoe 9 minutes ago
There have been many bashers here saying that NICE wouldn't even speak to the company, and it would be next year or later before they would be able to treat patients with payment from the UK healthcare system. It seems like they're very wrong and the system may be ready for patients very shortly af
NWBO
dennisdave dennisdave 9 minutes ago
so it's your belief Linda dares not to disclose negative material news Ofcourse she will but I think they will probably do that when there is no more escape route IF there is bad news to report. The 10K left them no option had they prior to that received bad news so I am pretty sure they didn't rece
NWBO
manibiotech manibiotech 9 minutes ago
I agree with your points . However there were medicines last year which got approved by MHRA but NICE decided not to get them covered by NHS same day or so. Those companies would have been in discussions with NICE before MHRA approval . So not really sure it is absolutely comforting . Looks like the
NWBO
fwb fwb 9 minutes ago
You have issues,
find a woman
Let her HELP YOU get RIGHT... if you know what I mean
PLTR
I-Glow I-Glow 9 minutes ago
I believe there is a caveat to that provision as the company also has to be Deficienct in another listing requirement.

TK, can explain it much better as well as others.

IG
MULN
ddls ddls 9 minutes ago
4/28/25, Buy: 525,000, Neutral: 4,076,000, Sell: 11,275,500

One last day buy ask slap trade to make this junk look good.
BIEL
archilles archilles 9 minutes ago
Isn’t there a newly graduated law student recently passed the bar exam lawyer who will take on this case for experience for small pro bono fees. This should be a relatively easy to identify the bad guys and the victims. What we have here are the victim shareholders, who got ripped off, versus the
ENZC

Your Recent History

TSXV
NVN.P
Navion Capital II
LSE
0F2S
Linedata Services
TSXV
AROC.P
Argo Opportunity
NASDAQ
SXTC
China SXT Pharmaceuticals
BIT
P1SIE8
BNP Paribas Issuance
NASDAQ
TSDD
GraniteShares ETF Trust ...
LSE
AUGM
Augmentum Fintech
LSE
DVNO
Develop North
USOTC
CYRAY
Cyrela Brazil Realty (PK)
LSE
2CIT
Ls 2x Citi
LSE
0MVK
Augros Cosmetic Packaging
USOTC
AAGIY
AIA (PK)
DOWI
DWCDLS
DJ US Delivery Services ...
BIT
P1SNZ3
BNP Paribas Issuance
USOTC
QLIS
Qualis Innovations (PK)
LSE
0HQ3
Brown-forman
Delayed Upgrade Clock
ADVFN Logo
Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads